Vaginal Estrogen After Breast Cancer: What Newer Studies Show
Intimate HealthArticleDryness, painful sex and repeat UTIs are common after breast cancer treatment, yet only about 1 in 20 survivors uses vaginal estrogen. Several large observational studies, including a 2025 meta-analysis, haven't found higher recurrence or death rates among users. The decision still belongs with your oncology team.

Breast cancer treatment, especially hormone-blocking medicines, often brings on or worsens vaginal dryness, burning, painful sex and repeat urinary infections. Vaginal estrogen treats these symptoms well, but many survivors and clinicians worry about using any estrogen after breast cancer.1 In large studies, only about 5% of survivors used it.12 Our guide to what the evidence shows about vaginal estrogen covers how little reaches the bloodstream for most women.
What the newer studies found
Scotland and Wales, 2024. Researchers followed about 49,000 women aged 40 to 79 with breast cancer. After adjusting for cancer stage, grade and other factors, women who used vaginal estrogen had no higher risk of dying from breast cancer than women who used no hormone therapy.1 The authors said this supports guidelines that vaginal estrogen can be considered for survivors with these symptoms.1
U.S. claims data, 2023. Among about 42,000 survivors with genitourinary symptoms, including about 10,600 with estrogen receptor-positive cancer, the risk of recurrence within 5 years was similar whether or not they used vaginal estrogen.2
Meta-analysis, 2025. Pooling 8 observational studies, vaginal estrogen use wasn’t linked to higher recurrence, breast cancer deaths or overall deaths.3
The limits
All of these are observational studies, not randomized trials. Women who chose vaginal estrogen may have differed in ways the researchers couldn’t fully measure. Follow-up in some studies was relatively short.2
Talk it through with your oncologist
Important details include:
- Your cancer type and whether it was hormone receptor-positive
- Which treatment you take now. Women taking aromatase inhibitors often get extra caution, because those medicines work by lowering estrogen.
- Whether nonhormonal options have helped. Our guide to vaginal moisturizers and lubricants explains them.
Our articles on numbing gel before sex, UTIs after sex and bleeding on tamoxifen cover related concerns.
Try: “Since starting my breast cancer medicine, sex hurts and I keep getting bladder infections. Moisturizers haven’t been enough. Can we talk about whether low-dose vaginal estrogen is reasonable for me?”
Down There, Decoded includes a Down-There Log and a See script for appointments. Use them to track symptoms and bring specific questions to your oncology visit. Explore the intimate-health playbook.
This article is for general educational purposes only and is not medical advice. It isn't a substitute for diagnosis or treatment from a qualified healthcare professional who knows your health history. Decisions about vaginal estrogen after breast cancer, especially if you take an aromatase inhibitor or tamoxifen, should be made with your oncologist. Any vaginal bleeding after menopause should be checked. If you think you may be having a medical emergency, call 911 or your local emergency number right away. This article discusses published research. Girl Playbook does not endorse any specific product, test, or provider.
Girl Playbook sells this book. It provides education and worksheets, not individualized medical care.
Sources
The research behind this article, in the order it’s cited. How we source our articles.
- JAMA Oncology (full text via PubMed Central), 2024Vaginal Estrogen Therapy Use and Survival in Females With Breast Cancer (opens in a new tab)abcd
- Obstetrics and Gynecology (abstract via Europe PMC), 2023Safety of Vaginal Estrogen Therapy for Genitourinary Syndrome of Menopause in Women With a History of Breast Cancer (opens in a new tab)abc
- American Journal of Obstetrics and Gynecology (abstract via Europe PMC), 2025Vaginal estrogen use in breast cancer survivors: a systematic review and meta-analysis of recurrence and mortality risks (opens in a new tab)↩
Spotted something out of date? Tell us and we’ll check it.


